AME临床研究评论｜奥希替尼作为T790M阴性EGFR突变型NSCLC的二线治疗有效吗？

文章预览

医学评论英文版原文： Economopoulou P, Kotsantis I, Psyrri A. Is osimertinib effective as 2nd line treatment in T790M-negative EGFR mutant NSCLC? AME Clin Trials Rev 2024;2:25. 被点评研究： Takeda M, Shimokawa M, Nakamura A, et al. A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy. Lung Cancer 2023;177:44-50. 奥希替尼作为T790M阴性EGFR突变型NSCLC的二线治疗有效吗？ Panagiota Economopoulou , Ioannis Kotsantis, Amanda Psyrri Oncology Unit, 2nd Department of Internal Medicine, Attikon University Hospital, Haidari, Greece 翻译：陈建乐 关键词： 奥希替尼；表皮生长因子受体 (EGFR)；T790M 突变；耐药机制 引言 晚期非小细胞肺癌（NSCLC）是一种异质性疾病，近年来，我们见证了由众多基因突变作为预 ………………………………